GSK plc
GSK
$51.84
-$0.53-1.01%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.46B | 11.52B | 10.67B | 9.47B | 10.40B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.46B | 11.52B | 10.67B | 9.47B | 10.40B |
| Cost of Revenue | 3.48B | 3.02B | 2.89B | 2.43B | 3.25B |
| Gross Profit | 7.98B | 8.51B | 7.78B | 7.04B | 7.15B |
| SG&A Expenses | 3.55B | 2.92B | 2.85B | 2.59B | 3.36B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -577.21M | -689.04M | -328.61M | -215.37M | 153.68M |
| Total Operating Expenses | 9.29B | 7.37B | 7.47B | 6.56B | 9.11B |
| Operating Income | 2.17B | 4.16B | 3.20B | 2.91B | 1.28B |
| Income Before Tax | 1.26B | 3.31B | 2.52B | 2.65B | 721.01M |
| Income Tax Expenses | 296.58M | 420.70M | 321.94M | 423.18M | 79.40M |
| Earnings from Continuing Operations | 966.88M | 2.89B | 2.20B | 2.23B | 641.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -121.03M | -176.64M | -271.17M | -186.40M | -111.42M |
| Net Income | 845.86M | 2.71B | 1.93B | 2.05B | 530.19M |
| EBIT | 2.17B | 4.16B | 3.20B | 2.91B | 1.28B |
| EBITDA | 3.58B | 5.15B | 4.74B | 3.95B | 2.37B |
| EPS Basic | 0.21 | 0.67 | 0.47 | 0.50 | 0.13 |
| Normalized Basic EPS | 0.28 | 0.57 | 0.40 | 0.38 | 0.14 |
| EPS Diluted | 0.21 | 0.66 | 0.47 | 0.50 | 0.13 |
| Normalized Diluted EPS | 0.27 | 0.56 | 0.39 | 0.37 | 0.14 |
| Average Basic Shares Outstanding | 4.02B | 4.03B | 4.06B | 4.09B | 4.08B |
| Average Diluted Shares Outstanding | 4.09B | 4.10B | 4.11B | 4.14B | 4.15B |
| Dividend Per Share | 0.24 | 0.22 | 0.21 | 0.20 | 0.20 |
| Payout Ratio | 101.57% | 32.29% | 45.46% | 37.68% | 147.83% |